Forest Pharmaceuticals manufactures and distributes the drugs developed by its parent, Forest Laboratories. Its production lines crank out prescription tablets, capsules, and liquids at facilities in Ohio. It then packages the products at facilities in Missouri, New York, and Ohio. The company's facilities in Missouri serve as Forest Laboratories' national distribution hub, taking in products manufactured at other facilities and shipping them out to customers throughout the US and Puerto Rico. Forest Pharmaceuticals also maintains customer support services to provide product information to prescribing physicians and patients. The company's facilities also house sales and marketing offices.
Services provided by Forest Pharmaceuticals' distribution center include warehousing, logistics, and delivery services. Its packaging centers process more than 16 billion solid dose medications and 2 million liters of liquid medications per year; these products are produced at Forest Laboratories' European plants as well as by the Forest Pharmaceuticals' facility in Ohio. The company's support staff, known as the medical information and communication department, includes a team of pharmacists that educate and inform patients and physicians about the Forest products.
Forest Pharmaceuticals' sales force, consisting of some 3,000 representatives, targets its efforts on marketing its parents branded prescription drugs, including central nervous system (CNS) and cardiovascular products, to physicians, hospitals, pharmacies, and other health-care entities throughout the US. The company's top selling products include antidepressants Celexa and Lexapro, as well as Namenda for Alzheimer's disease and Savella for fibromyalgia.
The sales force is a key driver in the success of Forest's product launches, including antibiotic Teflaro in 2010 and respiratory drug Daliresp in 2011. Such launches are increasingly important to the overall organization's success as older products lose their patent protection; for instance, bestseller Lexapro began facing generic competition in 2012.
▲ Show Less▼ Show Full Description